Rising Cancer Survival Rates Drive Growth In The Cancer Supportive Care Drugs Market: Pivotal Factor Influencing Cancer Supportive Care Drugs Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Cancer Supportive Care Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size for drugs related to supportive care for cancer patients has shown a consistent growth in recent years. It's forecasted to expand from a value of $20.83 billion in 2024 to $21.85 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.9%. Factors contributing to this growth in the historic period include the aging population, higher instances of chemotherapy, a surge in demand for antiemetics, a growing preference for procuring medications from online pharmacies and drug stores, increased awareness about supportive care, higher acceptance of personalized medicine, and a mounting emphasis on palliative care.

How Will the Cancer Supportive Care Drugs Market Size Evolve and Grow by 2029?
The market for cancer supportive care drugs is projected to steadily rise in size over the upcoming years, expected to reach a worth of $26.1 billion by the year 2029 at a compounded annual growth rate of 4.5%. This historic growth predicted for the forecast period can be associated with growing awareness regarding the side effects caused by cancer treatment, escalating instances of breast cancer in women, the existence of specialized medication programs, increasing demand for internet-based doctor consultations, and the enhancement of the pharmaceutical industry's supply chain, along with a rise in the number of cancer survivors. Key trends expected in the forecast period encompass progress in targeted treatments, incorporation of biobehavioral interventions, execution of survival care strategies, assimilation of nutritional support, advancements in managing pain techniques, and the implementation of symptom monitoring platforms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report

What Drivers Are Propelling the Growth of Cancer Supportive Care Drugs Market Forward?
The anticipated growth of the cancer supportive care drugs market is linked to the increased survival rate amongst cancer patients. This rate refers to the proportion of patients who live for a certain period, commonly five years, after a cancer diagnosis. Factors contributing to survival include early detection, treatment advancements, access to high-quality healthcare, the patient's overall health, the severity and type of cancer, along with socioeconomic factors. Cancer supportive care drugs play a role in heightening these rates by managing side effects like pain, nausea, and anemia. This, in turn, allows patients to better withstand their treatments and fully complete their therapy, potentially leading to better results. To illustrate, as of January 2022, the US government's National Cancer Institute has projected a 24.4% rise in the number of cancer survivors over the coming decade, approximating 22.5 million survivors by 2032. Consequently, the upward trend in cancer patient survival rates is fueling the cancer supportive care drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15749&type=smp

Which Emerging Trends Are Transforming the Cancer Supportive Care Drugs Market in 2025?
Leading businesses active in the cancer support care drug market are focusing on the creation of combination therapies to tackle the complexities and difficulties associated with cancer treatment. These combined therapies strategically use multiple therapeutic agents to hit different cancer growth and survival points, with the goal of obtaining more thorough and long-lasting results than single-agent therapies. For example, Merck, a pharmaceutical company based in the United States, received approval from the US federal agency Food and Drug Administration in November 2023 for their combination therapy involving KEYTRUDA, an anti-PD-1 therapy, with gemcitabine and cisplatin, aimed at treating patients suffering from advanced unresectable or metastatic biliary tract cancer (BTC). This therapeutic combination has demonstrated promising potential in enhancing overall survival rates and offering a fresh treatment alternative for this challenging disease.

What Are the Key Segments in the Cancer Supportive Care Drugs Market?
The cancer supportive care drugs market covered in this report is segmented -

1) By Type: Erythropoiesis Stimulating Agents, Granulocyte Colony Stimulating Factors, Antiemetics, Bisphosphonates, Opioids, Nonsteroidal Anti Inflammatory Drugs, Other Types
2) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer, Stomach Cancer, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Other Channels

Subsegments:
1) By Erythropoiesis Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa, Methoxy Polyethylene Glycol-Epoetin Beta
2) By Granulocyte Colony Stimulating Factors: Filgrastim, Pegfilgrastim, Lenograstim
3) By Antiemetics: 5-HT3 Receptor Antagonists, NK1 Receptor Antagonists, Corticosteroids
4) By Bisphosphonates: Zoledronic Acid, Pamidronate, Ibandronate
5) By Opioids: Morphine, Fentanyl, Oxycodone
6) By Nonsteroidal Anti Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Celecoxib
7) By Other Types: Steroids, Anxiolytics, Appetite Stimulants

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15749&type=smp

Who Are the Key Players Shaping the Cancer Supportive Care Drugs Market's Competitive Landscape?
Major companies operating in the cancer supportive care drugs market are Pfizer Inc., Johnson & Johnson, Merck, AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, F Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., Fagron Group, Heron Therapeutics Inc., Athenex Inc., Acrotech Biopharma LLC

What Geographic Markets Are Powering Growth in the Cancer Supportive Care Drugs Market?
North America was the largest region in the cancer supportive care drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer supportive care drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15749

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.